Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 14/20 | 0.79 |
| ▸ | STK39 | Q9UEW8 | 3/20 | 0.70 |
| ▸ | PARG | Q86W56 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692674 | 1.00 | PNLIP (0.79) | PNLIPSTK39PARGALDH1A1NPC1 | |
| SCHEMBL24438029 | 0.93 | PNLIP (0.83) | PNLIPSTK39PARGALDH1A1MEN1 | |
| SCHEMBL29655258 | 0.93 | PNLIP (0.83) | PNLIPSTK39PARGALDH1A1MEN1 | |
| SCHEMBL24438157 | 0.89 | ALDH1A1 (0.70) | PNLIPSTK39ALDH1A1NPC1MAPT | |
| SCHEMBL30692657 | 0.89 | ALDH1A1 (0.70) | PNLIPSTK39ALDH1A1NPC1MAPT | |
| SCHEMBL24438299 | 0.87 | PNLIP (0.80) | PNLIPSTK39PARG | |
| SCHEMBL30692665 | 0.87 | PNLIP (0.80) | PNLIPSTK39PARG | |
| SCHEMBL17740367 | 0.84 | ALDH1A1 (0.77) | ALDH1A1NPC1MAPTHPGDRAB9A | |
| SCHEMBL11468587 | 0.83 | ALDH1A1 (0.68) | PNLIPALDH1A1NPC1MAPTHPGD | |
| SCHEMBL24438042 | 0.83 | ALDH1A1 (0.76) | PNLIPALDH1A1NPC1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-12-21 | — | — | US | disclosed |
| EP-4243799-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | The Trustees of Indiana University (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022103572-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022103572-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSPBP1, HSP90AB1 | PNLIP 841/4885STK39 3354/4885PARG 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.